Moneycontrol Be a Pro
Get App
you are here: HomeNewsBusinessIPO
Last Updated : Sep 06, 2017 02:53 PM IST | Source: Moneycontrol.com

Avoid to Bharat Road Network: Choice Broking

Choice Broking has come out with its report on Bharat Road Network . The research firm has recommended to “ Avoid ” the IPO in its research report as on September 04, 2017

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Bharat Road Network Ltd. (BRNL) is a road BOT company in India, focused on development, implementation, operation and maintenance of roads/highways projects. The company have a project portfolio consisting of six BOT Projects, of which two are operational under final COD, three are operational under provisional COD and one is under construction.

•Out of the total net proceeds from the issue, around Rs. 3,725mn will be utilized to acquire subordinated debt advanced/held by SREI in the identified SPVs. Additionally around Rs. 515mn will be given as interest free subordinate debt to its subsidiary to part finance the project. Rest of the net proceeds will be utilized for general corporate purposes.

BRNL generates revenue mainly from consultancy fee. Over FY13-17, on standalone basis too, the company has reported loss, with loss increasing from Rs. 166.3mn in FY13 to Rs. 307.5mn in FY17. In the near term we are not anticipating any improvement in the business and thus on standalone basis also it may continue to report losses.

BRNL will be utilizing around Rs. 3,725mn from the net from the issue to acquire subordinated debt advanced/held by SREI in the identified SPVs. By this mechanism, the company will become creditors in the SPVs. Thus interest expenses from the SPV will be an income for the BRNL. This arrangement might increase the cash flow for the company (i.e. interest income plus non cash expenses in the SPV), but is not likely turn the SPVs profitable as there is no reduction in the debt levels.

Close

Coming on the valuation front, considering the profitability of BRNL and the above mentioned peers, it seems that the issue is aggressively priced. Thus considering the above observations we assign a “AVOID” rating for the issue.

For all IPO stories, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions

Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.
First Published on Sep 4, 2017 05:35 pm
Loading...
Sections
Follow us on
Available On
Trusted By 1cr Families
Medlife Health Comes Home